Active, not recruitingPhase 3NCT05021536
Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment
Studying Amyotrophic lateral sclerosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Amylyx Pharmaceuticals Inc.
- Principal Investigator
- Amylyx Study DirectorAmylyx Pharmaceuticals
- Intervention
- Placebo(other)
- Enrollment
- 664 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (30)
- Barrow Neurological Institute, Phoenix, Arizona, United States
- University of Southern California, Los Angeles, California, United States
- University of California Irvine, Orange, California, United States
- California Pacific Medical Center Research Institute, San Francisco, California, United States
- University of Colorado, Aurora, Colorado, United States
- University of Florida, Gainesville, Florida, United States
- University of South Florida, Tampa, Florida, United States
- Emory University, Atlanta, Georgia, United States
- Augusta University Neuroscience Center, Augusta, Georgia, United States
- Northwestern University, Chicago, Illinois, United States
- Johns Hopkins University School of Medicine Outpatient Center, Baltimore, Maryland, United States
- Healey & AMG Center for ALS Research at Massachusetts General Hospital, Boston, Massachusetts, United States
- University of Massachusetts, Worcester, Massachusetts, United States
- Hennepin Healthcare Research Institute, Minneapolis, Minnesota, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05021536 on ClinicalTrials.govOther trials for Amyotrophic lateral sclerosis
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07401186Stimulation-Based Modulation of Spinal and Cortical Sensory PathwaysPeter C. Gerszten, MD
- RECRUITINGNCT07467187Invasive Home Ventilation in DenmarkRigshospitalet, Denmark
- RECRUITINGNCT07259980A Study to Learn More About the Long-Term Safety of Tofersen (Qalsody) in Participants With Superoxide Dismutase 1 (SOD-1) Amyotrophic Lateral Sclerosis (ALS)Biogen
- RECRUITINGNCT07502677Diagnostic Accuracy of SleepImage Technology for Detecting Respiratory Failure in Patients With Amyotrophic Lateral SclerosisRoyal Brompton & Harefield NHS Foundation Trust
- RECRUITINGNANCT07446114Functional Outcomes and Control Using Synchron BCI - CanadaSynchron, Inc.
- ENROLLING BY INVITATIONPHASE2, PHASE3NCT07410806HEALEY ALS Platform Trial - Regimen I NUZ-001Merit E. Cudkowicz, MD
- ENROLLING BY INVITATIONNANCT07298486Impact of Robotic Glove Use on Quality of Life, Grip Strength and Fine Motor Control in ALSNova Southeastern University
- ACTIVE NOT RECRUITINGPHASE1NCT07204977Acamprosate in C9orf72 Hexanucleotide Repeat Expansion Amyotrophic Lateral Sclerosis (ACALS)National Institute of Neurological Disorders and Stroke (NINDS)